Madrigal Pharmaceuticals, Inc. (MDGL)
USD 302.78
(-2.49%)
USD 302.78
(-2.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 380.49 Million USD | 29.61% |
| 2022 | 293.57 Million USD | 21.07% |
| 2021 | 242.48 Million USD | 17.33% |
| 2020 | 206.67 Million USD | 117.61% |
| 2019 | 94.97 Million USD | 133.45% |
| 2018 | 40.68 Million USD | 26.89% |
| 2017 | 32.06 Million USD | 27.11% |
| 2016 | 25.22 Million USD | -62.69% |
| 2015 | 67.61 Million USD | -19.46% |
| 2014 | 83.95 Million USD | -4.12% |
| 2013 | 87.55 Million USD | 43.33% |
| 2012 | 61.08 Million USD | 15.23% |
| 2011 | 53.01 Million USD | 2.54% |
| 2010 | 51.7 Million USD | -18.84% |
| 2009 | 63.7 Million USD | -33.86% |
| 2008 | 96.32 Million USD | 43.85% |
| 2007 | 66.95 Million USD | 13.2% |
| 2006 | 59.15 Million USD | -16.9% |
| 2005 | 71.18 Million USD | 56.37% |
| 2004 | 45.51 Million USD | 53.79% |
| 2003 | 29.59 Million USD | 305.9% |
| 2002 | 7.29 Million USD | 1718.45% |
| 2001 | 401 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 176.27 Million USD | 16.07% |
| 2024 Q1 | 151.86 Million USD | 29.76% |
| 2024 Q3 | 176.32 Million USD | 0.03% |
| 2023 Q2 | 86.45 Million USD | 10.36% |
| 2023 Q1 | 78.33 Million USD | -8.16% |
| 2023 FY | 379.96 Million USD | 29.43% |
| 2023 Q3 | 98.53 Million USD | 13.98% |
| 2023 Q4 | 117.03 Million USD | 18.78% |
| 2022 FY | 293.57 Million USD | 21.07% |
| 2022 Q2 | 70.27 Million USD | 22.03% |
| 2022 Q1 | 57.58 Million USD | -10.86% |
| 2022 Q4 | 85.29 Million USD | 6.08% |
| 2022 Q3 | 80.41 Million USD | 14.43% |
| 2021 Q2 | 61.74 Million USD | 16.54% |
| 2021 Q1 | 52.97 Million USD | -11.04% |
| 2021 Q3 | 63.16 Million USD | 2.3% |
| 2021 Q4 | 64.6 Million USD | 2.28% |
| 2021 FY | 242.48 Million USD | 17.33% |
| 2020 FY | 206.67 Million USD | 117.61% |
| 2020 Q4 | 59.55 Million USD | 1.31% |
| 2020 Q3 | 58.78 Million USD | 16.81% |
| 2020 Q1 | 38 Million USD | 26.88% |
| 2020 Q2 | 50.32 Million USD | 32.42% |
| 2019 Q3 | 24.19 Million USD | 6.57% |
| 2019 FY | 94.97 Million USD | 133.45% |
| 2019 Q4 | 29.95 Million USD | 23.8% |
| 2019 Q2 | 22.7 Million USD | 25.3% |
| 2019 Q1 | 18.11 Million USD | 25.36% |
| 2018 FY | 40.68 Million USD | 26.89% |
| 2018 Q1 | 7.06 Million USD | -20.67% |
| 2018 Q2 | 7.82 Million USD | 10.71% |
| 2018 Q3 | 11.33 Million USD | 44.81% |
| 2018 Q4 | 14.45 Million USD | 27.54% |
| 2017 FY | 32.06 Million USD | 27.11% |
| 2017 Q3 | 8.63 Million USD | 2.35% |
| 2017 Q2 | 8.43 Million USD | 38.91% |
| 2017 Q1 | 6.07 Million USD | -21.67% |
| 2017 Q4 | 8.91 Million USD | 3.17% |
| 2016 FY | 25.22 Million USD | -62.69% |
| 2016 Q2 | 3.48 Million USD | -45.88% |
| 2016 Q3 | 14.09 Million USD | 303.86% |
| 2016 Q4 | 7.75 Million USD | -44.96% |
| 2016 Q1 | 6.44 Million USD | -37.89% |
| 2015 FY | 67.61 Million USD | -19.46% |
| 2015 Q4 | 10.38 Million USD | -40.32% |
| 2015 Q3 | 17.39 Million USD | -10.82% |
| 2015 Q2 | 19.5 Million USD | -4.07% |
| 2015 Q1 | 20.33 Million USD | 2.2% |
| 2014 Q3 | 19.44 Million USD | -10.38% |
| 2014 Q2 | 21.7 Million USD | -5.26% |
| 2014 FY | 83.95 Million USD | -4.12% |
| 2014 Q1 | 22.9 Million USD | -2.29% |
| 2014 Q4 | 19.89 Million USD | 2.29% |
| 2013 FY | 87.55 Million USD | 43.33% |
| 2013 Q3 | 21.79 Million USD | -1.22% |
| 2013 Q4 | 23.44 Million USD | 7.57% |
| 2013 Q2 | 22.06 Million USD | 8.91% |
| 2013 Q1 | 20.25 Million USD | 14.43% |
| 2012 Q4 | 17.7 Million USD | 21.76% |
| 2012 Q2 | 14.13 Million USD | -3.93% |
| 2012 Q1 | 14.71 Million USD | 7.69% |
| 2012 Q3 | 14.53 Million USD | 2.87% |
| 2012 FY | 61.08 Million USD | 15.23% |
| 2011 Q2 | 13.36 Million USD | 10.36% |
| 2011 Q1 | 12.1 Million USD | -2.36% |
| 2011 Q3 | 13.88 Million USD | 3.88% |
| 2011 Q4 | 13.66 Million USD | -1.58% |
| 2011 FY | 53.01 Million USD | 2.54% |
| 2010 Q2 | 12.4 Million USD | -6.6% |
| 2010 FY | 51.7 Million USD | -18.84% |
| 2010 Q4 | 12.4 Million USD | -8.9% |
| 2010 Q3 | 13.61 Million USD | 9.75% |
| 2010 Q1 | 13.28 Million USD | 13.9% |
| 2009 Q1 | 26.7 Million USD | 0.78% |
| 2009 Q2 | 13.1 Million USD | -50.94% |
| 2009 Q3 | 12.23 Million USD | -6.64% |
| 2009 Q4 | 11.66 Million USD | -4.68% |
| 2009 FY | 63.7 Million USD | -33.86% |
| 2008 Q1 | 19.78 Million USD | 15.78% |
| 2008 FY | 96.32 Million USD | 43.85% |
| 2008 Q4 | 26.5 Million USD | -4.41% |
| 2008 Q3 | 27.72 Million USD | 24.23% |
| 2008 Q2 | 22.31 Million USD | 12.8% |
| 2007 Q2 | 17.46 Million USD | 2.67% |
| 2007 Q1 | 17.01 Million USD | 30.81% |
| 2007 FY | 66.95 Million USD | 13.2% |
| 2007 Q3 | 15.39 Million USD | -11.86% |
| 2007 Q4 | 17.08 Million USD | 10.99% |
| 2006 Q2 | -14.92 Million USD | 0.0% |
| 2006 Q4 | 13 Million USD | -15.45% |
| 2006 Q1 | -14.92 Million USD | 3.64% |
| 2006 FY | 59.15 Million USD | -16.9% |
| 2006 Q3 | 15.38 Million USD | 203.04% |
| 2005 Q3 | -26.68 Million USD | 0.0% |
| 2005 Q4 | -15.49 Million USD | 41.95% |
| 2005 Q2 | -26.68 Million USD | -244.26% |
| 2005 FY | 71.18 Million USD | 56.37% |
| 2005 Q1 | 18.49 Million USD | 0.0% |
| 2004 FY | 45.51 Million USD | 53.79% |
| 2004 Q1 | 5.62 Million USD | 0.0% |
| 2003 FY | 29.59 Million USD | 305.9% |
| 2002 FY | 7.29 Million USD | 1718.45% |
| 2001 FY | 401 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | 201.11 Million USD | -89.193% |
| Jaguar Health, Inc. | 42.01 Million USD | -805.619% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -124.777% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -570.371% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 78.862% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -351.236% |
| ContextLogic Inc. | 387 Million USD | 1.681% |
| MiMedx Group, Inc. | 229.72 Million USD | -65.63% |
| MEI Pharma, Inc. | 34.78 Million USD | -993.851% |
| AlloVir, Inc. | 180.93 Million USD | -110.297% |
| Novavax, Inc. | 779.12 Million USD | 51.164% |
| Aptorum Group Limited | 10.56 Thousand USD | -3601035.718% |
| Ardelyx, Inc. | 169.93 Million USD | -123.904% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 14.637% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -13728.248% |
| Vaxcyte, Inc. | 468.04 Million USD | 18.705% |
| Precigen, Inc. | 84.18 Million USD | -351.997% |
| Pharming Group N.V. | 225.49 Million USD | -68.741% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -126.719% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -424.345% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -192.098% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -55.204% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1859.449% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1465.401% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1465.401% |
| Bicycle Therapeutics plc | 216.92 Million USD | -75.407% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -66.388% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1133.015% |
| Acelyrin, Inc. | 422.06 Million USD | 9.849% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -904.769% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -926.592% |
| Senti Biosciences, Inc. | 94.7 Million USD | -301.77% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -207.962% |
| AbCellera Biologics Inc. | 275.23 Million USD | -38.246% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1191.174% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -121.345% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -187.873% |
| Chimerix, Inc. | 93.38 Million USD | -307.431% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1016.315% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2079.618% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2635.484% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -650.589% |
| Elevation Oncology, Inc. | 45.44 Million USD | -737.267% |
| Alkermes plc | 996.24 Million USD | 61.807% |
| Fortress Biotech, Inc. | 200.19 Million USD | -90.063% |
| Fortress Biotech, Inc. | 200.19 Million USD | -90.063% |
| Agenus Inc. | 78.18 Million USD | -386.674% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1061.962% |
| Dyadic International, Inc. | 9.15 Million USD | -4057.201% |
| ImmuCell Corporation | 9.61 Million USD | -3856.345% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1609.864% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -141.104% |
| Lantern Pharma Inc. | 17.87 Million USD | -2028.343% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2257.31% |
| Incyte Corporation | 1.19 Billion USD | 68.039% |
| IO Biotech, Inc. | 91.44 Million USD | -316.102% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -369.389% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -5552.097% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -616.209% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1136.541% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -4402.378% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -349.143% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 5.716% |
| NextCure, Inc. | 67.63 Million USD | -462.556% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1185.199% |
| Onconetix, Inc. | 34.9 Million USD | -990.014% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -2885.219% |
| Opthea Limited | 191.96 Million USD | -98.209% |
| PDS Biotechnology Corporation | 43.04 Million USD | -783.945% |
| PureTech Health plc | 144.59 Million USD | -163.142% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -362.913% |
| Seer, Inc. | 110.49 Million USD | -244.371% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2950853.932% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1063.063% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -9552.242% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1181.908% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -109.87% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -125.899% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -138.127% |
| ChromaDex Corporation | 56.37 Million USD | -574.89% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1910.122% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -152.761% |
| CRISPR Therapeutics AG | 463.49 Million USD | 17.907% |
| Precision BioSciences, Inc. | 92.46 Million USD | -311.512% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -49.776% |
| Innoviva, Inc. | 132.15 Million USD | -187.919% |
| Summit Therapeutics Inc. | 87.68 Million USD | -333.93% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -438.992% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -307.043% |
| ESSA Pharma Inc. | 32.13 Million USD | -1084.088% |
| GlycoMimetics, Inc. | 39.28 Million USD | -868.546% |
| GT Biopharma, Inc. | 13.57 Million USD | -2702.711% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -73.086% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -46.669% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -603.58% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -3728.835% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -46.537% |
| Aptose Biosciences Inc. | 52.35 Million USD | -626.748% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -2540.431% |
| Soligenix, Inc. | 7.79 Million USD | -4781.126% |
| Century Therapeutics, Inc. | 56.07 Million USD | -578.597% |
| Kura Oncology, Inc. | 165.8 Million USD | -129.485% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -232.291% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -4473.819% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -15232.448% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -253.299% |
| Autolus Therapeutics plc | 196.72 Million USD | -93.414% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -349.456% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -226.738% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1863.04% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -18.255% |
| GRI Bio, Inc. | 11.33 Million USD | -3258.305% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -5292.746% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -190.028% |
| IGM Biosciences, Inc. | 265.59 Million USD | -43.264% |
| INmune Bio, Inc. | 29.89 Million USD | -1172.732% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -120.508% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -843.824% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2281.172% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2317.144% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -512.735% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -253.877% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -38.014% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -26.222% |
| Verastem, Inc. | 92.08 Million USD | -313.205% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2021.055% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -104.871% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -213.405% |
| Histogen Inc. | 14.27 Million USD | -2566.031% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2270.966% |
| Surrozen, Inc. | 18.55 Million USD | -1951.191% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2451.096% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -7375.017% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -537.633% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1383.589% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -709.463% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -4884.984% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -113.599% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -685.371% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -55.302% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2376.128% |
| Apollomics, Inc. | 54.14 Million USD | -602.8% |
| Amarin Corporation plc | 272.35 Million USD | -39.705% |
| Mesoblast Limited | 5.9 Million USD | -6346.899% |
| Turnstone Biologics Corp. | 78.33 Million USD | -385.711% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -55.863% |
| Synaptogenix, Inc. | 8.31 Million USD | -4476.65% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2508.638% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -50.36% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1041.6% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -4208.525% |
| Exelixis, Inc. | 1.58 Billion USD | 76.021% |
| Better Therapeutics, Inc. | 38.26 Million USD | -894.449% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -63.972% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 55.508% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3122.613% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -4631.416% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1168.616% |
| Gritstone bio, Inc. | 148.37 Million USD | -156.444% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -452.557% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2225.739% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1363.671% |
| Insmed Incorporated | 949.26 Million USD | 59.917% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2325.119% |
| MediWound Ltd. | 18.86 Million USD | -1916.621% |
| OmniAb, Inc. | 83.89 Million USD | -353.538% |
| Alector, Inc. | 248.8 Million USD | -52.931% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -62.391% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -628.208% |
| Zai Lab Limited | 547.47 Million USD | 30.5% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 4.555% |
| Aura Biosciences, Inc. | 84.99 Million USD | -347.69% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -53.961% |
| Immunic, Inc. | 99.22 Million USD | -283.476% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -139.288% |
| Veracyte, Inc. | 357.93 Million USD | -6.304% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 95.78% |
| FibroGen, Inc. | 398.11 Million USD | 4.425% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2577.664% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -5424.084% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -5239.746% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 88.313% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1370.63% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -20.204% |
| TG Therapeutics, Inc. | 198.47 Million USD | -91.71% |
| Galecto, Inc. | 35.62 Million USD | -967.999% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -835.132% |
| Fortrea Holdings Inc. | 457.3 Million USD | 16.795% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -601.013% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1217.598% |
| XBiotech Inc. | 37.51 Million USD | -914.385% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -452.557% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1742.685% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -167.84% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -284.048% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -243.668% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 60.293% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1219.106% |
| Vaxxinity, Inc. | 56.05 Million USD | -578.839% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 11.644% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1605.624% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -243.2% |
| NexImmune, Inc. | 28.16 Million USD | -1250.833% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -6779.399% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2026.566% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 86.485% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1394.544% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3147.973% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -199.457% |
| Ainos, Inc. | 12.95 Million USD | -2837.589% |
| Pluri Inc. | 22.48 Million USD | -1592.598% |
| Prothena Corporation plc | 282.4 Million USD | -34.734% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -90.227% |
| Celularity Inc. | 215.05 Million USD | -76.927% |
| Rallybio Corporation | 78.93 Million USD | -382.055% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1847.068% |
| MeiraGTx Holdings plc | 151.07 Million USD | -151.854% |
| Omeros Corporation | 94.75 Million USD | -301.575% |
| Humacyte, Inc. | 23.49 Million USD | -1519.339% |
| Immunocore Holdings plc | 308.04 Million USD | -23.522% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -11124.071% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -338.031% |
| Blueprint Medicines Corporation | 722.86 Million USD | 47.362% |
| CalciMedica, Inc. | 21.81 Million USD | -1644.034% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -409.638% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -137.01% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -122.129% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -29.008% |
| Pulmatrix, Inc. | 22.03 Million USD | -1626.545% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1000.495% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -328.168% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 31.015% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -424.453% |
| Cytokinetics, Incorporated | 173.61 Million USD | -119.165% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1005.482% |
| Nutriband Inc. | 5.73 Million USD | -6535.751% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -772.437% |
| Vor Biopharma Inc. | 126.03 Million USD | -201.895% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 68.003% |
| Evogene Ltd. | 27.79 Million USD | -1269.183% |
| ProKidney Corp. | 151.52 Million USD | -151.116% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -412.971% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -4846.49% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 38.053% |
| CorMedix Inc. | 48.95 Million USD | -677.192% |
| BioLineRx Ltd. | 50.8 Million USD | -648.978% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -152.486% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -899.412% |
| Atai Life Sciences N.V. | 125.78 Million USD | -202.497% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -366.07% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -367.388% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -50.66% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1062.175% |
| MediciNova, Inc. | 10.9 Million USD | -3390.704% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -195.37% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5141.335% |
| GeoVax Labs, Inc. | 6.02 Million USD | -6218.251% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 20.124% |
| Biomea Fusion, Inc. | 126.13 Million USD | -201.658% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 70.995% |
| Mereo BioPharma Group plc | 35.84 Million USD | -961.593% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -99.12% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -65.466% |
| Absci Corporation | 73.66 Million USD | -416.515% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1279.508% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -184.824% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -57.125% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -45.201% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -82.936% |
| Allakos Inc. | 196.05 Million USD | -94.075% |
| Imunon, Inc. | 20.31 Million USD | -1773.402% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -235.33% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -3.224% |
| BioAtla, Inc. | 129.68 Million USD | -193.396% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3122.613% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2301.666% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -348.075% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -811.193% |
| XOMA Corporation | 46.46 Million USD | -718.923% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -242.262% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -167.084% |
| aTyr Pharma, Inc. | 12.97 Million USD | -2831.628% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -267.076% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -120.105% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -49.352% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -917.151% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -4526.196% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2164.049% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -16632.675% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -27.121% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -5554.797% |
| UroGen Pharma Ltd. | 138.88 Million USD | -173.959% |
| Sutro Biopharma, Inc. | 243 Million USD | -56.577% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -5130.457% |
| Orgenesis Inc. | 45.75 Million USD | -731.558% |
| Entera Bio Ltd. | 8.86 Million USD | -4194.537% |
| GH Research PLC | 41.22 Million USD | -823.041% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1380.068% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -358.136% |
| Xencor, Inc. | 306.97 Million USD | -23.949% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -7612.33% |
| Replimune Group, Inc. | 234.77 Million USD | -62.07% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1756.994% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -98.386% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -5554.797% |
| Portage Biotech Inc. | 18.19 Million USD | -1990.752% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -5141.335% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -262.512% |
| OncoCyte Corporation | 25.63 Million USD | -1384.167% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -6142.135% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3221.061% |
| Purple Biotech Ltd. | -22.46 Million USD | 1793.577% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2208.835% |
| scPharmaceuticals Inc. | 65.17 Million USD | -483.78% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -4401.454% |
| HilleVax, Inc. | 133.34 Million USD | -185.347% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -3599.524% |
| Tharimmune, Inc. | 9.45 Million USD | -3924.19% |
| Genprex, Inc. | 31.06 Million USD | -1125.013% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -102.903% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1112.659% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -49638.039% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -6885.527% |
| OKYO Pharma Limited | 8243.57 USD | -4615570.153% |
| Savara Inc. | 15.74 Million USD | -2316.615% |
| Curis, Inc. | 58.35 Million USD | -552.037% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1032.112% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -7371.711% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -4999.799% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1308.097% |
| BeiGene, Ltd. | 3.28 Billion USD | 88.423% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1808.272% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 23.712% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -147.635% |
| Erasca, Inc. | 141.52 Million USD | -168.854% |
| bluebird bio, Inc. | 240.23 Million USD | -58.387% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -8305.085% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 78.211% |
| DBV Technologies S.A. | 92.16 Million USD | -312.865% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -8305.085% |
| Moderna, Inc. | 6.39 Billion USD | 94.049% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -792.994% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -2548.587% |
| Molecular Templates, Inc. | 63.09 Million USD | -503.091% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -470.45% |
| Travere Therapeutics, Inc. | 472 Million USD | 19.387% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -165.504% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -512.893% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -776.436% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -82.817% |
| MacroGenics, Inc. | 217.21 Million USD | -75.17% |
| RenovoRx, Inc. | 11.39 Million USD | -3238.856% |
| Adicet Bio, Inc. | 152.03 Million USD | -150.264% |
| Prime Medicine, Inc. | 186.63 Million USD | -103.867% |
| Aditxt, Inc. | 25.95 Million USD | -1366.223% |
| Adagene Inc. | 41.83 Million USD | -809.595% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5105.074% |
| Quantum-Si incorporated | 111.65 Million USD | -240.766% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -121.412% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2510.112% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -962.185% |
| SciSparc Ltd. | 9.01 Million USD | -4122.572% |
| Vericel Corporation | 142.04 Million USD | -167.879% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4295.411% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1547.983% |
| Generation Bio Co. | 144.46 Million USD | -163.379% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -358.263% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -340.083% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -28.668% |
| Invivyd, Inc. | 205.75 Million USD | -84.927% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -427.302% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -3957.108% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -405.616% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -3598.804% |
| 2seventy bio, Inc. | 289.88 Million USD | -31.257% |
| ADMA Biologics, Inc. | 66.58 Million USD | -471.435% |
| Clene Inc. | 41.07 Million USD | -826.39% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -2870.795% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -594.386% |
| GeoVax Labs, Inc. | 6.02 Million USD | -6218.251% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -8.081% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -935.87% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1028.131% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -266.913% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1067.56% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -123.456% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 50.438% |
| Evaxion Biotech A/S | 22.27 Million USD | -1608.559% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -180.718% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -61.995% |
| Trevena, Inc. | 38.41 Million USD | -890.54% |
| Surrozen, Inc. | 18.55 Million USD | -1951.191% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -375.947% |
| Cingulate Inc. | 22.75 Million USD | -1571.835% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 5178.697% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -751.85% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -4521.068% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -271.006% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 49.542% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -512.972% |
| Clearmind Medicine Inc. | 8.74 Million USD | -4252.829% |
| Kronos Bio, Inc. | 128.11 Million USD | -196.989% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -352.583% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -12872.995% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -277.375% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1219.814% |
| ImmunityBio, Inc. | 362.87 Million USD | -4.857% |
| Korro Bio, Inc. | 84.53 Million USD | -350.11% |
| Kineta, Inc. | 21.15 Million USD | -1698.525% |
| BioVie Inc. | 31.95 Million USD | -1090.903% |
| Codexis, Inc. | 66.51 Million USD | -472.02% |
| Celularity Inc. | 215.05 Million USD | -76.927% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -67.9% |
| Celcuity Inc. | 66.23 Million USD | -474.504% |
| Virax Biolabs Group Limited | 6.54 Million USD | -5711.705% |
| Cibus, Inc. | 320.3 Million USD | -18.792% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -784.874% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1024.264% |
| IN8bio, Inc. | 30.33 Million USD | -1154.231% |
| Kodiak Sciences Inc. | 277.32 Million USD | -37.204% |
| Annexon, Inc. | 143.72 Million USD | -164.743% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -198.215% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1560.902% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -59352.5% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 51.193% |
| Eyenovia, Inc. | 25.4 Million USD | -1397.636% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -171.173% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6740.992% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -380.831% |
| Arcellx, Inc. | 200.19 Million USD | -90.059% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -728.967% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -75.821% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -3721.392% |
| Moolec Science SA | 52.75 Million USD | -621.311% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -522.356% |
| Geron Corporation | 70.44 Million USD | -440.163% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -717.568% |
| Royalty Pharma plc | 862.4 Million USD | 55.88% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -304.473% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -3979.132% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1581.488% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -83.096% |
| Humacyte, Inc. | 23.49 Million USD | -1519.339% |
| Structure Therapeutics Inc. | 102.77 Million USD | -270.222% |
| 89bio, Inc. | 151.2 Million USD | -151.644% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -374.837% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -2516.891% |
| Genelux Corporation | 24.33 Million USD | -1463.575% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1021.646% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -120.107% |
| Notable Labs, Ltd. | 14.77 Million USD | -2476.141% |
| Liquidia Corporation | 87.98 Million USD | -332.46% |
| Mustang Bio, Inc. | 48.5 Million USD | -684.512% |
| Immunovant, Inc. | 282.7 Million USD | -34.589% |
| Quantum-Si incorporated | 111.65 Million USD | -240.766% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1587.793% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1689.138% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -272.991% |
| Acasti Pharma Inc. | 11.3 Million USD | -3266.923% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1560.025% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2281.172% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -717.533% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -33436.287% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2295.166% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1204.99% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -819.428% |
| PepGen Inc. | 84.76 Million USD | -348.878% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1184.115% |
| United Therapeutics Corporation | 885.1 Million USD | 57.011% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1561.772% |
| Solid Biosciences Inc. | 104.31 Million USD | -264.757% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1062.688% |
| Immuneering Corporation | 58.41 Million USD | -551.391% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -7375.017% |
| Silo Pharma, Inc. | 3.92 Million USD | -9601.937% |
| Belite Bio, Inc | 31.66 Million USD | -1101.516% |
| XOMA Corporation | 46.46 Million USD | -718.923% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -463.281% |
| Bionomics Limited | 17.89 Billion USD | 97.873% |
| Apogee Therapeutics, Inc. | 93 Million USD | -309.122% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1166.413% |
| uniQure N.V. | 285.08 Million USD | -33.467% |
| Cassava Sciences, Inc. | 105.95 Million USD | -259.104% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -5105.074% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -95.923% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1071.586% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -4479.459% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1194.424% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -6740.992% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2577.664% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4180.526% |
| Altimmune, Inc. | 30.55 Million USD | -1145.242% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 11.027% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1166.413% |
| Compugen Ltd. | 43.97 Million USD | -765.334% |
| Peak Bio, Inc. | 1249.13 USD | -30460780.773% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -413.351% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1600.009% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -56.461% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1233.062% |
| Zura Bio Limited | 62.63 Million USD | -507.452% |
| PolyPid Ltd. | 21.04 Million USD | -1708.011% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2237.773% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1233.062% |
| Instil Bio, Inc. | 85.78 Million USD | -343.546% |
| argenx SE | 1.53 Billion USD | 75.188% |
| Immunome, Inc. | 122.82 Million USD | -209.8% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -684.965% |
| Verona Pharma plc | 67.15 Million USD | -466.625% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1369.948% |
| Shattuck Labs, Inc. | 93.61 Million USD | -306.452% |
| CervoMed Inc. | 14.95 Million USD | -2443.802% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -438.161% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -4353.371% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -646.071% |
| Moolec Science SA | 52.75 Million USD | -621.311% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2213.265% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -187.047% |
| AnaptysBio, Inc. | 181.56 Million USD | -109.561% |
| Design Therapeutics, Inc. | 78.19 Million USD | -386.63% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -337.146% |
| NeurAxis, Inc. | 8.82 Million USD | -4213.427% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -2923.409% |
| Lumos Pharma, Inc. | 38.66 Million USD | -884.084% |
| Achilles Therapeutics plc | 75.25 Million USD | -405.609% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1369.948% |
| 180 Life Sciences Corp. | 13.47 Million USD | -2723.194% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1335.702% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -12872.995% |
| Nutriband Inc. | 5.73 Million USD | -6535.751% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -243.47% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -583.694% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -647.845% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -475.646% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -603.02% |
| Palisade Bio, Inc. | 13.32 Million USD | -2756.577% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -737.931% |
| Beam Therapeutics Inc. | 554.19 Million USD | 31.342% |
| Neurogene Inc. | 55.58 Million USD | -584.555% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -53.124% |
| AEON Biopharma, Inc. | 48.42 Million USD | -685.678% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -293.44% |
| Sesen Bio, Inc. | 78.38 Million USD | -385.444% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -355.526% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -2922.953% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 15.632% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -332.923% |
| Athira Pharma, Inc. | 125.46 Million USD | -203.266% |
| Vaccinex, Inc. | 23.45 Million USD | -1522.238% |
| HCW Biologics Inc. | 21.02 Million USD | -1709.514% |
| XOMA Corporation | 46.46 Million USD | -718.923% |
| Nektar Therapeutics | 190.9 Million USD | -99.314% |
| Arvinas, Inc. | 480 Million USD | 20.73% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -16632.675% |
| Merus N.V. | 200.49 Million USD | -89.779% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -268.145% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -999.064% |
| Rezolute, Inc. | 70.38 Million USD | -440.577% |
| Clene Inc. | 41.07 Million USD | -826.39% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2223.147% |
| BeyondSpring Inc. | 24.86 Million USD | -1430.247% |
| Synlogic, Inc. | 58.53 Million USD | -550.065% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2026.626% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -8370.525% |
| Peak Bio, Inc. | 1249.13 USD | -30460780.773% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -529.481% |
| Krystal Biotech, Inc. | 160.42 Million USD | -137.179% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -40.596% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -9.326% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -17542.231% |
| MannKind Corporation | 125.59 Million USD | -202.95% |
| Ikena Oncology, Inc. | 84.57 Million USD | -349.881% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -3844.19% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -324.656% |
| Gossamer Bio, Inc. | 183.75 Million USD | -107.063% |
| CohBar, Inc. | 12.38 Million USD | -2971.415% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -650.13% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1279.508% |
| Legend Biotech Corporation | 583.14 Million USD | 34.751% |
| Mural Oncology plc | 192.07 Million USD | -98.102% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -466.661% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2256.702% |
| Disc Medicine, Inc. | 91.12 Million USD | -317.554% |
| Champions Oncology, Inc. | 28.11 Million USD | -1253.597% |
| REGENXBIO Inc. | 321.15 Million USD | -18.477% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -6997.172% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -582.431% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -876.616% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -232.726% |
| Vaxart, Inc. | 90.72 Million USD | -319.39% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -4365.911% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -789.132% |
| Cellectis S.A. | 97.32 Million USD | -290.974% |
| Longeveron Inc. | 21.25 Million USD | -1690.569% |
| Repare Therapeutics Inc. | 167.35 Million USD | -127.356% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 72.039% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -403.002% |
| Revolution Medicines, Inc. | 498.76 Million USD | 23.712% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -5620.024% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -765.669% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -410.117% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -446.415% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3340.289% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 92.031% |
| Denali Therapeutics Inc. | 527.23 Million USD | 27.831% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -4295.411% |
| Veru Inc. | 101.34 Million USD | -275.435% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1525.565% |
| Cingulate Inc. | 22.75 Million USD | -1571.835% |
| Passage Bio, Inc. | 108.38 Million USD | -251.047% |
| Context Therapeutics Inc. | 25.07 Million USD | -1417.576% |
| Exicure, Inc. | 14.07 Million USD | -2603.154% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -84.649% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -778.723% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4046.061% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -50.702% |
| Nuvalent, Inc. | 149.49 Million USD | -154.526% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -4616.755% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -267.097% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1673.957% |
| OmniAb, Inc. | 83.89 Million USD | -353.538% |
| Anew Medical, Inc. | 1.3 Million USD | -29150.001% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1061.323% |
| Lipocine Inc. | 15.08 Million USD | -2423.16% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -455.363% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -399.653% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -843.824% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -231.318% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1599.857% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 42.709% |
| Ocugen, Inc. | 71.56 Million USD | -431.664% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -305.361% |
| Q32 Bio Inc. | 92.68 Million USD | -310.548% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1696.996% |
| Alumis Inc. Common Stock | 158.17 Million USD | -140.555% |
| Equillium, Inc. | 50.6 Million USD | -651.879% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -509.711% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2636.288% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1916.93% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -710.411% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -250.797% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -2970.317% |
| Dominari Holdings Inc. | 23.83 Million USD | -1496.375% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4025.621% |
| vTv Therapeutics Inc. | 11.9 Million USD | -3095.566% |
| Bio-Techne Corporation | 563.03 Million USD | 32.421% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 6.925% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -41.577% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -187.651% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -2540.316% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -132.441% |
| Nkarta, Inc. | 131.65 Million USD | -189.021% |
| BioCardia, Inc. | 12.12 Million USD | -3039.147% |
| Iterum Therapeutics plc | 47.46 Million USD | -701.584% |